KZR-616 + Placebo
Phase 2Completed 0 views this week 0 watching💤 Quiet
Interest: 25/100
25
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Polymyositis
Conditions
Polymyositis, Dermatomyositis
Trial Timeline
Jan 14, 2020 → Apr 6, 2022
NCT ID
NCT04033926About KZR-616 + Placebo
KZR-616 + Placebo is a phase 2 stage product being developed by Kezar Life Sciences for Polymyositis. The current trial status is completed. This product is registered under clinical trial identifier NCT04033926. Target conditions include Polymyositis, Dermatomyositis.
What happened to similar drugs?
0 of 1 similar drugs in Polymyositis were approved
Approved (0) Terminated (0) Active (1)
Hype Score Breakdown
Clinical
12
Activity
8
Company
5
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT04033926 | Phase 2 | Completed |
Competing Products
6 competing products in Polymyositis
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| tacrolimus | Astellas Pharma | Pre-clinical | 26 |
| Placebo + BAF312 | Novartis | Phase 2 | 27 |
| BAF312 + Placebo | Novartis | Phase 2 | 27 |
| MEDI7734 + Placebo | Amgen | Phase 1 | 29 |
| Abatacept subcutaneous + Placebo | Bristol Myers Squibb | Phase 3 | 40 |
| KZR-616 | Kezar Life Sciences | Phase 2 | 25 |